A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma

This trial is testing a new drug called SHR-A1912 — either alone or combined with other treatments — in people with B-cell non-Hodgkin's lymphoma (a type of blood cancer). It includes both newly diagnosed patients and those whose lymphoma has returned or stopped responding to treatment. **You may be eligible if...** - You are 18 or older - You have been diagnosed with B-cell non-Hodgkin's lymphoma (confirmed by biopsy) - You are either newly diagnosed or have had lymphoma that relapsed or became resistant after at least one prior treatment - Your general health is good (ECOG 0–1) - You have at least one measurable tumor - Your expected survival is more than 3 months **You may NOT be eligible if...** - You received CAR-T cell therapy or stem cell transplant recently - Your lymphoma has spread to the brain or spinal fluid - You have active HIV, hepatitis B, or hepatitis C - You have had a severe heart condition - You have active uncontrolled infection or unexplained fever Talk to your doctor to see if this trial is right for you.